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Phase angle (PhA), by bioelectrical impedance analysis, has been used in patients with several 45 
diseases; however, its prognostic value in patients with gastrointestinal and hepatobiliary–pancreatic 46 
(HBP) cancer is unclear. The present study aimed to investigate the impact of PhA on postoperative 47 
short-term outcomes and long-term survival in these patients. 48 
Research Methods & Procedures 49 
This retrospective study reviewed data of 501 patients with gastrointestinal and HBP cancers who 50 
underwent first resection surgery and divided the data into the following groups according to the 51 
preoperative PhA quartile values by sex: high-PhA group with the highest quartile (Q4), 52 
normal-PhA group with middle quartiles (Q3 and Q2), and low-PhA group with the lowest quartile 53 
(Q1). Preoperative nutritional statuses, postoperative short-term outcomes during hospitalization, 54 
and 5-year survival between three groups were compared. Cox proportional hazard models were 55 
used to evaluate the prognostic effect of PhA. 56 
Results 57 
PhA positively correlated with body weight, skeletal muscle mass, and handgrip strength, and 58 
negatively correlated with age and C-reactive protein levels. The low-PhA group showed a high 59 
prevalence of malnutrition (48%) than normal-PhA (25%), and high-PhA (9%) (P < 0.001). The 60 
incidence of postoperative severe complications was 10% in all patients [14% in low-PhA, 12% in 61 
normal-PhA, and 4% in high-PhA (P = 0.018)]. The incidence of prolonged postoperative high care 62 
unit or/and intensive care unit stays was 8% in all patients [16% in low-PhA, 8% in normal-PhA, 63 
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and 2% in high-PhA (P < 0.001)]. The 5-year survival rate was 74% in all patients [68% in low-PhA, 64 
74% in normal-PhA, and 79% in high-PhA (P < 0.001)]. The multivariate analysis demonstrated 65 
that a low-PhA group was an independent risk factor for mortality (hazard ratio, 1.99; 95% 66 
confidence interval 1.05–3.90; P = 0.034). 67 
Conclusion 68 
PhA is a useful short-term and long-term postoperative prognostic marker for patients with 69 
gastrointestinal and HBP cancers. 70 
 71 
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Malnutrition is highly prevalent among patients with pancreatic (83%), gastric (83%), and 77 
colorectal (60%) cancers [1]. Preoperative malnutrition is associated with an increase in 78 
postoperative complications, prolonged length of hospital stay, and increased mortality [1, 2]. 79 
Therefore, it is crucial to precisely assess the nutritional status of patients. 80 
Bioelectrical impedance analysis (BIA) has widely been used for measuring body composition 81 
in clinical settings because it is easy, inexpensive, and noninvasive [3]. Phase angle (PhA) is a 82 
parameter of BIA that is derived from resistance (R) and reactance (Xc) measurements. R is the 83 
pure resistance of the alternating electric current flowing throughout the body, and Xc is the 84 
resistance of the double-layered cell membrane [4]. PhA is considered as an indicator of cell 85 
membrane integrity [5]. PhA is higher in men than in women, decreases with aging, and varies 86 
among races in healthy individuals [5]. PhA has been reported as a nutritional and prognostic 87 
indicator in non-oncologic and oncologic patients. There have been reports that low PhA is a 88 
marker of poor prognosis in patients who have human immunodeficiency virus [6], are on 89 
hemodialysis [7], or have liver cirrhosis [8]. In oncologic patients, there have been reports that 90 
low PhA is a marker of poor prognosis in patients with advanced pancreatic cancer [9], advanced 91 
colorectal cancer [10], hepatocellular carcinoma [11], head and neck cancer [12, 13], breast 92 
cancer [14], lung cancer [15, 16]. Further studies showed similar finding in more diverse 93 
oncologic populations: a group with various types of cancers (including gastrointestinal, head and 94 
neck, gynecologic, and others) [17, 18, 19], critically ill cancer patients admitted to an intensive 95 
care unit (ICU) [20], and patients with advanced cancer admitted to an acute palliative care unit 96 
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[21].  97 
Although PhA has been associated with survival in patients with pancreatic cancer [9], 98 
colorectal cancer [10], and hepatocellular carcinoma [11], the association of PhA with 99 
postoperative short-term outcomes such as postoperative complications and hospital length of 100 
stay is unknown. Moreover, the nutritional and clinical significances of PhA in patients with 101 
cancer remain ambiguous. 102 
In the present study, we assessed the usefulness of preoperative PhA assessment for providing 103 
nutritional or prognostic information in patients with gastrointestinal and HBP cancers scheduled 104 
for elective surgery. Our primary objective was to assess associations between preoperative PhA 105 
values and postoperative short-term outcomes or long-term survival. The secondary objective was 106 
to consider the nutritional and clinical significances of PhA by evaluating possible associations 107 
between PhA and other clinical parameters. 108 
  109 
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Materials and Methods 110 
Patients 111 
This retrospective, observational study included data from 922 patients admitted for elective 112 
gastrointestinal and HBP cancer surgery at the Digestive Surgery and Transplantation center in the 113 
Tokushima University Hospital between July 2014 and March 2018. After applying the inclusion 114 
criteria (patients with gastric, colorectal, liver, bile duct, or pancreatic cancers and those who 115 
underwent first radical resection surgery), we collected records of 795 patients. We excluded 16 116 
patients who canceled surgery, 13 with benign tumors, 45 with metachronous metastatic cancer, 20 117 
with combined resection of primary and synchronous metastatic cancer, 7 with recurrent 118 
hepatocellular carcinoma, 11 with stage 0 or unknown stage, and 182 missing PhA data measured 119 
via BIA. Finally, we analyzed data of 501 patients (Figure 1). This study was conducted in 120 
accordance with the tenets of the Declaration of Helsinki, and the ethical committee of the 121 
Tokushima University Hospital approved the protocol (No. 3157), and all patients agreed to 122 





Figure 1. Selection of patients analyzed in this study 126 
PhA, phase angle; BIA, bioelectrical impedance analysis 127 
 128 
Data collection 129 
We collected data on age, sex, height, weight, cancer site, cancer stage, serum biochemical data, 130 
postoperative complications, postoperative length of high care unit (HCU) or/and ICU stay, date of 131 
operation, and date of death from electronic medical records.  132 
 133 
Nutritional assessment 134 
All preoperative nutritional assessments were performed routinely during the period between 135 
admission and surgery by well-trained registered dieticians. All patients were assessed at least 136 
within 1 week before the surgery to 1 day before the surgery. Baseline nutritional assessments 137 
included subjective global assessment (SGA), anthropometries [arm circumference (AC), triceps 138 
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skinfold thickness (TSF), mid-upper arm muscle area (AMA), and handgrip strength], BIA, and 139 
serum biochemical tests [albumin, hemoglobin, total lymphocyte, and C-reactive protein (CRP)]. 140 
The dieticians performed SGA and classified the patients as A (well-nourished) and B or C (with 141 
moderate or severe malnutrition), as defined previously [22]. Body mass index (BMI) was 142 
calculated as weight/height2 (kg/m2). Five well-trained dietitians measured AC and TSF at the 143 
midpoint of the triceps of the non-dominant arm with adipometer calipers (Abbot Laboratories, 144 
Tokyo, Japan). AMA was calculated using the following equation: AMA (cm2) = [AC (cm) − {π × 145 
TSF (cm)}]2/4π [23]. Grip strength of both hands was measured in a standing position using a 146 
dynamometer (Takei Scientific Instruments, Niigata, Japan). These tests were repeated twice for 147 
each hand, and the highest value for each hand was included in the overall mean. Biochemical tests 148 
were conducted at the Department of Clinical Laboratory in the Tokushima University Hospital, and 149 
these data were collected from electronic medical records. Serum albumin concentrations were 150 
measured by the modified bromocresol purple method, serum CRP concentrations were measured 151 
by the latex agglutination method, hemoglobin was measured by the colorimetric method, and total 152 
lymphocyte counts were determined by flow cytometry. We calculated prognostic nutritional index 153 
(PNI)—a nutritional and immunological parameter—as follows: 10 × serum albumin concentration 154 
(g/dL) + 0.005 × lymphocyte count (number/mm2) in the peripheral blood as described by Onodera 155 
et al [24]. The cut-off value of PNI was determined to be 40 based on an original investigation [24]. 156 
Sarcopenia was diagnosed by the cut-off points of low handgrip strength and low skeletal muscle 157 
index suggested by the Asian Working Group of Sarcopenia. [25]. The cut-off values of handgrip 158 
strength were 26 kg in men and 18 kg in women, and the cut-off values of low skeletal muscle mass 159 
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were 7.0 kg/m2 in men and 5.7 kg/m2 in women. We assessed cancer cachexia as described by 160 
Fearon et al [26]. 161 
 162 
BIA 163 
BIA was performed using Inbody770 (InBody, Tokyo, Japan), and R and Xc were measured 164 
using an eight-point tactile electrode and multi-frequency current. BIA was conducted in a 165 
standing position and was not conducted in patients with pacemakers or those who had difficulty 166 
standing. Patients fasted for at least 4 h before the measurement. PhA values at 50 kHz were 167 
calculated as follows: PhA (degrees) = arctan (Xc/R) × (180/π). In order to investigate the 168 
characteristics of patients with particularly high and low PhA, we divided patients into three 169 
groups according to the PhA quartile values by sex. The high-PhA group was PhA > 75th 170 
percentile (Q4), the low-PhA group was PhA ≦ 25th percentile (Q1), and the normal-PhA group 171 
was between 25th and 75th percentile (Q3 and Q2). The cut-off value of the 25th and 75th 172 
percentile was 4.4° and 5.5° in men, and 4.0° and 4.8° in women. 173 
 174 
Outcomes 175 
 The short-term outcomes were defined as the incidence of prolonged postoperative length of stay 176 
(≥ 3 days) in HCU or/and ICU or the incidence of severe postoperative complications. This was 177 
based on the usual clinical path of the Digestive Surgery and Transplantation Center in the 178 
Tokushima University Hospital, which is that patients stay in the HCU or/and ICU for up to 2 days 179 
postoperatively. Postoperative complications were assessed from the first day post-surgery until 180 
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discharge and were classified from grades 1 to 5 according to the Clavien–Dindo classification [27]. 181 
We defined complications of grade ≥3 as severe. The long-term outcome was defined as the 5-year 182 
survival rate. Survival time was calculated from the time of surgery to the last follow-up date (June 183 
30, 2019) or death. 184 
 185 
Statistical analysis 186 
We expressed non-normally distributed continuous variables as medians and interquartile 187 
ranges. We performed comparisons among three groups (high-, normal-, and low-PhA groups) and 188 
continuous variables using the Kruskal–Wallis analysis. We calculated statistical differences among 189 
the three groups using the Steel–Dwass test. We performed comparisons among three groups and 190 
categorical variables using the chi-squared test. We applied the Spearman correlation coefficient test 191 
to determine correlations between PhA and other nutritional indexes such as BMI, AC, AMA, TSF, 192 
handgrip strength, and serum biochemical data. The associations between PhA and postoperative 193 
short-term outcomes were performed using univariate and multivariate logistic regression analyses. 194 
Baseline variables with P < 0.1 in the univariate analysis were included in the multivariate models. 195 
We applied the Kaplan–Meier analysis to calculate survival time and the log-rank test to evaluate 196 
significant differences. For multiple comparisons, we used the Bonferroni correction. We used 197 
univariate and multivariate Cox proportional hazards regression models to calculate hazard ratios 198 
(HRs) and 95% confidence intervals (CIs) and to identify predictors for mortality. Any variables 199 
with P < 0.1 in univariate analysis were included in the multivariate Cox proportional hazard model. 200 
All statistical analyses were performed using the JMP version 13.0 software (SAS Institute, Cary, 201 
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NC, USA). We considered all values of P < 0.05 as statistically significant. We followed standard 202 
methods to estimate the appropriate sample size for multivariate logistic regression analyses and 203 
multivariate Cox proportional hazards regression models, with at least 10 outcomes required for 204 
each included independent variable. The sample size was calculated using data from our 205 
preliminary study, with an expected incidence of postoperative severe complications and prolonged 206 
postoperative HCU or/and ICU stays, and mortality rate of 10%, we required 400 (4×10/0.1) 207 
patients (40 incidents) to appropriately perform multivariate logistic regression analyses and 208 
multivariate Cox proportional hazards regression models with four variables. 209 
 210 





Patient characteristics 214 
Table 1 presents the characteristics of the 501 patients included in the study. Median 215 
(interquartile ranges) of PhA values was 5.0° (4.4°–5.5°) in men and 4.4° (4.0°–4.8°) in women. We 216 
divided the patients into low-, normal-, and high-PhA groups according to the quartile PhA values 217 
by sex. Age, height, body weight, BMI, PhA, and fat free mas (FFM) were significantly different 218 
among the three groups. 219 
 220 
Table 1. Patient characteristics 221 
  All Low-PhA Normal-PhA High-PhA 
P-value 
  n = 501 n = 125 n = 251 n = 125 
Age (years) 70 (63–76) 77 (70–83) 69 (64–69) 65 (56–72) <0.001 
Sex 
     
  Men 316 (63%) 79 (63%) 158 (63%) 79 (63%) 
1.000 
  Women 185 (37%) 46 (37%) 93 (37%) 46 (37%) 
Cancer site 
     
  Gastric 155 (31%) 33 (26%) 77 (31%) 45 (36%) 
0.459 
  Colorectal 201 (40%) 52 (42%) 98 (39%) 51 (41%) 
  Liver 75 (15%) 19 (15%) 36 (14%) 20 (16%) 
  Bile duct 38 (8%) 11 (9%) 22 (9%) 5 (4%) 




     
  I 176 (35%) 34 (27%) 89 (35%) 53 (42%) 
0.186 
  II 150 (30%) 40 (32%) 75 (30%) 35 (28%) 
  III 116 (23%) 30 (24%) 61 (24%) 25 (20%) 











BW (kg) 57.2 (49.9–65.3) 52.5 (44.4–59.8) 58.2 (51.2–65.1) 61.3 (53.4–69.1) <0.001 
BMI (kg/m2) 22.4 (20.6–24.5) 20.9 (19.0–23.0) 22.5 (20.7–24.4) 23.4 (21.8–25.4) <0.001 
PhA(°) 4.7 (4.2–5.3) 3.8 (3.5–4.1) 4.7 (4.5–5.1) 5.6 (5.1–6.0) <0.001 
FFM (kg) 42.5 (35.6-49.2) 38.4 (32.3-44.8) 43.2 (36.1-49.7) 46.0 (37.8-52.8) <0.001 
Surgery time 
(min) 
288 (240-348) 286 (229-350) 289 (240-347) 294 (246-339) 0.780 
BW, body weight; BMI, body mass index; PhA, phase angle; FFM, fat free mass 222 
Statistical analysis; Kruskal–Wallis analysis for continuous variables, chi-squared test for 223 
categorical variables. 224 
 225 
Correlation of phase angle to clinical parameters and nutritional markers 226 
Table 2 shows the correlation of PhA to clinical parameters and nutritional markers. We 227 
observed significant negative correlations between PhA and age and between PhA and serum CRP 228 
levels. Further, we observed positive correlations between PhA and height, body weight, BMI, AC, 229 
AMA, skeletal muscle mass, handgrip strength, albumin level, hemoglobin level, total lymphocyte 230 










Age (years) −0.47 <0.001 
Height (cm) 0.39 <0.001 
Body weight (kg) 0.48 <0.001 
Body mass index (kg/m2) 0.31 <0.001 
Arm circumference (cm) 0.41 <0.001 
Mid-upper arm muscle area (cm2) 0.48 <0.001 
Triceps skinfold thickness (mm) 0.00 0.935 
Skeletal muscle mass (kg) 0.60 <0.001 
Body fat mass (kg) 0.09 0.052 
Handgrip strength (kg) 0.68 <0.001 
Albumin (g/dL) 0.44 <0.001 
Hemoglobin (g/dL) 0.48 <0.001 
Total lymphocyte (/mm3) 0.17 <0.001 
C-reactive protein (mg/dL) −0.14 0.001 
PNI 0.43 <0.001 
PNI, prognostic nutritional index 235 
Statistical analysis; Spearman correlation coefficient test 236 
 237 
Comparison of the nutritional status in three groups 238 
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Table 3 shows the prevalence of malnutrition, sarcopenia, and cachexia in the low-, normal-, 239 
and high-PhA groups. According to the SGA, the rates of moderate or severe malnutrition were 240 
higher in the low-PhA group. The number of patients with low PNI, sarcopenia, and cachexia were 241 
significantly higher in the low-PhA group. 242 
 243 
Table 3. Prevalence of malnutrition, sarcopenia, and cachexia by phase angle 244 
    Low-PhA Normal-PhA High-PhA P-value 
SGA A 65 (52%) 187 (75%) 113 (91%) 
<0.001 
 B or C 60 (48%) 63 (25%) 11 (9%) 
PNI High 73 (59%) 196 (79%) 118 (95%) 
<0.001 
 Low 51 (41%) 52 (21%) 6 (5%) 
Non-sarcopenia 60 (57%) 175 (87%) 104 (94%) 
<0.001 
Sarcopenia 45 (43%) 26 (13%) 7 (6%) 
Non-cachexia 53 (44%) 150 (64%) 88 (73%) 
<0.001 
Cachexia  67 (56%) 86 (36%) 33 (27%) 
PhA, phase angle; SGA, subjective global assessment; PNI, prognostic nutritional index 245 
Statistical analysis; chi-squared test 246 
 247 
Association between PhA and postoperative short-term outcomes 248 
The incidence of postoperative severe complications (Clavien–Dindo classification grade ≥ 3) 249 
was 10% in all patients [14% in low-PhA group, 12% in normal-PhA group, and 4% in high-PhA 250 
group (P = 0.018)]. In the univariate analysis, presence of bile duct and pancreatic cancers, presence 251 
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of stage IV disease, and belonging to the normal- and low-PhA groups (as a categorical variables) 252 
were significant risk factors for postoperative complications (Table 4). In the multivariate analysis, 253 
there is a trend that PhA (as a continuous variable) can predict complications in postoperative 254 
period, but does not show a significant P-value [odds ratio (OR) = 0.68; 95% CI 0.44–1.06; P = 255 
0.088, shown in Table 4, multivariate 1]. Furthermore, there is a trend that belonging to the 256 
low-PhA group aids in predicting complications in postoperative period, although no significant 257 
P-value is observed (OR = 3.00; 95% CI 0.98–9.20; P = 0.055, shown in Table 4, multivariate 2). 258 
The incidence of prolonged postoperative HCU or/and ICU stays was 8% in all patients [16% in 259 
low-PhA group, 8% in normal-PhA group, and 2% in high-PhA group (P < 0.001)]. In the univariate 260 
analysis, age, presence of bile duct and pancreatic cancers, presence of stage IV disease, low PhA 261 
(as a continuous variable), and belonging to the low-PhA group (as a categorical variable) were 262 
significant risk factors for longer HCU or/and ICU stays (Table 5). In the multivariate analysis, PhA 263 
(as a continuous variable) remained an independent risk factor for longer HCU or/and ICU stays 264 
(OR = 0.54; 95% CI 0.31–0.92; P = 0.024, shown in Table 5, multivariate 1). Furthermore, 265 
belonging to the low-PhA group was an independent risk factor for longer HCU or/and ICU stays 266 
(OR = 5.69; 95% CI 1.38–23.39; P = 0.016, shown in Table 5, multivariate 2). 267 
 268 
Table 4. Univariate and multivariate analyses of risk factors associated with postoperative 269 
complications 270 





  OR 95% CI P-value 
 
OR 95% CI P-value 
 
OR 95% CI P-value 
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Age (years) 1.02 0.99–1.05 0.194 
 
- - - 
 
- - - 
Sex            
Men 1.00 - - 
 
1.00 - - 
 
1.00 - - 
Women 0.54 0.28–1.03 0.053 
 
0.29 0.13–0.63 0.002 
 
0.36 0.17–0.76 0.008 
Cancer site            
Colorectal 1.00 - - 
 
1.00 - - 
 
1.00 - - 
Gastric 0.68 0.27–1.76 0.430 
 
0.65 0.24–1.72 0.382 
 
0.64 0.24–1.72 0.377 
Liver 0.81 0.26–2.58 0.728 
 
0.69 0.21–2.23 0.533 
 
0.69 0.21–2.26 0.543 
Bile duct 9.43 3.99–22.28 <0.001 
 
12.83 4.95–33.26 <0.001 
 
12.59 4.83–32.81 <0.001 
Pancreas 9.89 4.01–24.39 <0.001 
 
10.35 3.77–28.41 <0.001 
 
9.79 3.57–26.88 <0.001 
Stage            
I 1.00 - - 
 
1.00 - - 
 
1.00 - - 
II 1.19 0.52–2.73 0.684 
 
0.50 0.18–1.38 0.182 
 
0.50 0.18–1.38 0.184 
III 1.88 0.83–4.22 0.128 
 
1.21 0.48–3.06 0.687 
 
1.19 0.47–3.01 0.714 
IV 4.25 1.84–9.84 <0.001 
 
1.45 0.52–4.04 0.475 
 
1.54 0.56–4.24 0.402 
PhA (°) 0.73 0.51–1.05 0.088 
 
0.68 0.44–1.06 0.088 
 
- - - 
PhA            
High 1.00 - - 
 
- - - 
 
1.00 - - 
Normal 3.14 1.18–8.31 0.022 
 
- - - 
 
2.60 0.91–7.41 0.075 
Low 4.04 1.45–11.25 0.008 
 
- - - 
 
3.00 0.98–9.20 0.055 
PhA, phase angle; OR, odds ratio; CI, confidence interval 271 
Multivariate 1: using PhA as a continuous variable 272 
Multivariate 2: using PhA as a categorical variable 273 




Table 5. Univariate and multivariate analyses of risk factors associated with postoperative length 276 
of HCU or/and ICU stay for ≥ 3 days 277 





  OR 95% CI P-value 
 
OR 95% CI P-value 
 
OR 95% CI P-value 
Age (years) 1.04 1.00–1.07 0.038 
 
1.01 0.97–1.06 0.556 
 
1.01 0.97–1.06 0.629 
Sex            
Men 1.00 - - 
 
- - - 
 
- - - 
Women 0.75 0.38–1.48 0.397 
 
- - - 
 
- - - 
Cancer site            
Colorectal 1.00 - - 
 
1.00 - - 
 
1.00 - - 
  Gastric 1.12 0.37–3.39 0.847 
 
1.19 0.38–3.76 0.770 
 
1.21 0.39–3.82 0.741 
  Liver 1.15 0.29–4.59 0.838 
 
1.21 0.30–4.95 0.791 
 
1.12 0.28–4.59 0.870 
  Bile duct 16.17 5.94–44.01 <0.001 
 
15.57 5.35–45.29 <0.001 
 
16.46 5.61–48.29 <0.001 
  Pancreas 16.63 5.88–47.03 <0.001 
 
14.73 4.78–45.34 <0.001 
 
15.03 4.78–47.21 <0.001 
Stage            
I 1.00 - - 
 
1.00 - - 
 
1.00 - - 
II 2.16 0.88–5.30 0.092 
 
0.80 0.27–2.35 0.682 
 
0.89 0.31–2.58 0.828 
III 1.77 0.66–4.72 0.257 
 
0.94 0.30–2.94 0.913 
 
0.94 0.30–2.92 0.910 
IV 4.81 1.83–12.64 0.001 
 
1.41 0.43–4.63 0.569 
 
1.42 0.43–4.64 0.566 
PhA (°) 0.47 0.31–0.71 <0.001 
 
0.54 0.31–0.92 0.024 
 
- - - 
PhA            
High 1.00 - - 
 
- - - 
 
1.00 - - 
Normal 3.33 0.97–11.48 0.057 
 
- - - 
 
2.25 0.59–8.50 0.232 
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Low 7.75 2.24–26.80 0.001 
 
- - - 
 
5.69 1.38–23.39 0.016 
PhA, phase angle; OR, odds ratio; CI, confidence interval 278 
Multivariate 1: using PhA as a continuous variable 279 
Multivariate 2: using PhA as a categorical variable 280 
Statistical analysis; univariate and multivariate logistic regression analyses 281 
 282 
Survival outcome 283 
Figure 2 shows the survival curves of the low-, normal-, and high-PhA groups. The 5-year 284 
survival rate was 74% in all patients (68% in low-PhA group, 74% in normal-PhA group, and 79% 285 
in high-PhA group). Overall mortality was significantly higher in the low-PhA group than in the 286 
normal-PhA (P = 0.008) and high-PhA (P = 0.007) group. 287 
 288 
 289 
Figure 2. Kaplan–Meier survival curves by phase angle 290 
We calculated the overall survival from the time of surgery to the last follow-up date or death. The 291 
solid line represents the high-PhA group; the dotted line, the normal-PhA group; and the dashed line, 292 
the low-PhA group. PhA, phase angle. 293 
20 
 
Statistical analysis; Kaplan–Meier analysis was used to calculate survival time and the log-rank test 294 
used to evaluate significant differences. For multiple comparisons, we used the Bonferroni 295 
correction. 296 
 297 
Table 6 shows the HR and 95% CI. In the univariate analysis, cancer site, cancer stage, and 298 
PhA (as both continuous and categorical variables) were significant risk factors for mortality, 299 
whereas age and sex were not. In the multivariate analysis, low PhA (as a continuous variable) was 300 
an independent risk factor for mortality (HR = 0.56; 95% CI 0.40–0.79; P < 0.001, shown in 301 
multivariate 1). Similarly, belonging to the low-PhA group (as a categorical variable) was a 302 
significant risk factor for mortality (HR = 1.99; 95% CI 1.05–3.90; P = 0.034, shown in multivariate 303 
2). 304 
 305 
Table 6. Univariate and multivariate Cox proportional hazard ratio 306 





  HR 95% CI P-value 
 
HR 95% CI P-value 
 
HR 95% CI P-value 
Age (years) 1.00 0.98–1.03 0.850 
 
- - - 
 
- - - 
Sex            
Men 1.00 
   
- - - 
 
- - - 
Women 0.70 0.42–1.12 0.142 
 
- - - 
 
- - - 
Cancer site            
Colorectal 1.00 
   
1.00 
   
1.00 
  
Gastric 1.11 0.56–2.19 0.763 
 
1.91 0.95–3.81 0.074 
 
1.89 0.93–3.83 0.138 
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Liver 2.62 1.36–5.04 0.005 
 
2.51 1.30–4.88 0.008 
 
2.31 1.19–4.52 0.017 
Bile duct 3.89 1.85–8.18 0.001 
 
0.53 0.24–1.18 0.017 
 
3.12 1.45–6.70 0.013 
Pancreas 7.69 3.89–15.20 <0.001 
 
4.96 2.44–10.09 <0.001 
 
4.47 2.13–9.36 <0.001 
Stage            
I 1.00 
   
1.00 
   
1.00 
  
II 3.67 1.45–11.18 0.005 
 
3.04 1.17–9.42 0.022 
 
3.48 1.34–10.75 0.010 
III 7.15 2.94–21.28 <0.001 
 
6.46 2.58–19.62 <0.001 
 
6.41 2.56–19.48 <0.001 
IV 24.68 10.51–72.26 <0.001 
 
18.25 7.35–55.47 <0.001 
 
17.71 7.14–53.75 <0.001 
PhA (°) 0.56 0.42–0.76 <0.001 
 
0.56 0.40–0.79 <0.001 
 
- - - 
PhA            
High 1.00 
   




Normal 1.21 0.67–2.28 0.530 
 
- - - 
 
1.04 0.57–1.98 0.910 
Low 2.38 1.28–4.59 0.006 
 
- - - 
 
1.99 1.05–3.90 0.034 
PhA, phase angle; HR, hazard ratio; CI, confidence interval 307 
Multivariate 1: using PhA as a continuous variable 308 
Multivariate 2: using PhA as a categorical variable 309 




We assessed the possible association between PhA and postoperative short- or long-term 312 
prognosis in patients with gastrointestinal and HBP cancers scheduled for resection surgeries and 313 
analyzed the association between PhA and nutritional or clinical variables. PhA positively 314 
correlated with skeletal muscle mass, biochemical nutritional or immunological markers, and 315 
handgrip strength, and negatively correlated with age and CRP. Low PhA was associated with a 316 
longer HCU or/and ICU stay. Low PhA was independently associated with poor survival. 317 
In the present study, we used the BIA method because it is easy to use, inexpensive, and 318 
non-invasive, and it requires no training. Although BIA-derived variables, such as skeletal muscle 319 
mass, have widely been used, measurement data on abnormal fluid balance, such as edema or 320 
ascites, should be carefully interpreted [5, 28]. BIA does not directly measure body composition; its 321 
accuracy depends on regression equations [5, 28, 29]. This is one of the limitations of BIA for 322 
assessing the muscle mass. In an edematous state, resistance is reduced, and cellular function may 323 
also be negatively affected, leading to decreased reactance [21]. This results in decreased 324 
impedance and thus a higher lean body mass is calculated by regression equations via BIA. By 325 
contrast, PhA is a raw data that describes the relation between two vector components of impedance 326 
(R and Xc) of the human body to an alternating electric current [6]. Reactance reflects “the ability 327 
of cell membranes to act as imperfect capacitors” [6]. Therefore, PhA has been considered as an 328 
indicator of cell membrane integrity [6]. In an edematous state, resistance is reduced, and cellular 329 
function may also be negatively affected, leading to decreased reactance and thus a lower PhA [21]. 330 
Therefore, PhA is different from the other BIA parameters such as lean body mass [19] and has the 331 
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advantage of being more useful in predicting prognosis than other BIA parameters. However, its 332 
biological and clinical interpretations remain unclear. 333 
Studies on healthy individuals have shown that PhA is significantly higher in men and that 334 
racial differences exist [5]. PhA values have been reported at 6.55° ± 1.10° for Asians, 6.82° ± 1.13° 335 
for Caucasians, 7.21° ± 1.19° for African-Americans, and 7.33° ± 1.13°for Hispanics. Another study 336 
involving healthy individuals showed that age, race, height, FFM were PhA determinants in both 337 
men and women [30]. They suggested the need for specific reference values for each population. 338 
Indeed, in studies conducted in the American population [9, 10], the median PhA value of patients 339 
with pancreatic and colorectal cancers were 5.0° and 5.57°, respectively; however, the median PhA 340 
values of Japanese patients in the present study were lower with 4.6° and 4.7° in cases of pancreatic 341 
and colorectal cancers, respectively. Our results indicate the racial differences of PhA, and the 342 
reference value suggested in this study may be useful for Asian populations. 343 
In the present study, we observed a correlation between PhA and various nutritional or clinical 344 
variables. Consistent with other reports [5], PhA was higher in men than in women and was 345 
positively correlated with BMI and negatively correlated with age. Interestingly, PhA showed a 346 
positive correlation with AMA (muscle mass index) but not with TSF (fat mass index). PhA 347 
positively correlated with handgrip strength (muscle function index). In addition, the ratio of 348 
sarcopenia was higher in the low-PhA group than in the other groups. These findings suggest that 349 
PhA reflects the nutritional status of patients, particularly their muscle volume and function. On 350 
analyzing PhA by cancer stage, we observed that PhA is significantly higher in patients with stage I 351 
disease than in others (P < 0.05); the PhA values were 4.9° (4.3°–5.5°) in stage I, 4.6° (4.1°–5.1°) in 352 
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stage II, 4.7° (4.1°–5.2°) in stage III, and 4.6° (4.1°–5.0°) in stage IV. Moreover, PhA showed a 353 
negative correlation with CRP level. These results suggest that PhA presents both nutritional 354 
information and disease severity. 355 
Preoperative low PhA has been associated with postoperative length of stay or complications in 356 
cardiac patients undergoing surgery [31], in patients with advanced ovarian cancer [32], in patients 357 
with head and neck cancer [33], and in patients with gastric cancer [34]. In our study, there was a 358 
trend toward low PhA predicting complications in the postoperative period, this did not reach 359 
significance. One recent report showed that standardized PhA had no association with postoperative 360 
complications (P = 0.199) in patients undergoing resection of colorectal cancer [35]. The authors of 361 
this report discussed the merit of assessing PhA, namely that it is non-invasive and of low cost, and 362 
argued that further research with a larger sample size was needed to demonstrate the usefulness of 363 
standardized PhA in predicting clinical outcomes [35]. Malnutrition has been reported to be 364 
associated with reduced immune competence and more infections [36]. Preoperative malnutrition is 365 
well recognized as a risk factor for increased morbidity in patients undergoing major surgery [37, 366 
38]. Low PhA is a marker of depletion of muscular mass and of resources in general [32]. Thus, low 367 
PhA may be associated with the reduced immune response to cancer and may influence 368 
postoperative recovery. We observed that low PhA was a risk factor for prolonged postoperative 369 
HCU or/and ICU stays. Typically, patients stay in the HCU or/and ICU for only up to 2 days 370 
postoperatively in our center according to the clinical path; however, patients with low PhA exhibit 371 
a high incidence of postoperative complications, and their length of stay exceeded 3 days. Our 372 
results suggest that PhA is a useful postoperative short-term prognostic indicator. 373 
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In the present study, we observed that PhA was an independent risk factor for mortality, despite 374 
adjusting for other factors (such as cancer site and cancer stage). In a study conducted on patients 375 
with cancer, a standardized PhA according to age, sex, and BMI was an independent 6-month 376 
survival prognostic factor [17]. However, the report included various types of cancer such as 377 
gastrointestinal, head and neck, and urogenital cancers; therefore, their results do not necessarily 378 
apply to patients with gastrointestinal and HBP cancers. Studies on patients with gastrointestinal 379 
cancer have also been reported [9, 10, 11]. Studies on patients with pancreatic [9] and colon [10] 380 
cancers and on patients with hepatocellular carcinoma [11] have demonstrated that low PhA is a 381 
poor prognosis factor. However, these reports do not provide data regarding the association between 382 
PhA and postoperative short-term outcomes, and the analysis of survival outcomes in these studies 383 
were not adjusted by sex and cancer stage, which was one of the limitations of these studies.  384 
This study has several key strengths. The first is the use of BIA which is an easy, noninvasive, 385 
and inexpensive tool to predict short-term and long-term prognosis. The second strength is that, to 386 
the best of our knowledge, this is the first report indicating that PhA can predict both short- and 387 
long-term prognosis in patients with gastrointestinal and HBP cancers. The third strength is that our 388 
results provide the reference values in patients with gastrointestinal and HBP cancer by sex in 389 
Asians for the first time. Most studies of PhA have been conducted in Western or American 390 
populations, and data for Asian populations are scarce. Our results indicate that the lowest quartile 391 
value (4.4° in men and 4.0° in women) can be useful as a prognostic cut-off value in patients with 392 
gastrointestinal and HBP cancers. 393 
The limitations of this study must be acknowledged. The study has a retrospective design and 394 
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further prospective intervention studies are warranted to elucidate whether the improvement of 395 
preoperative PhA leads to better prognoses. There were many missing data of BIA measurements. It 396 
would be best if we could analyze each cancer type separately; however, we could not analyze each 397 
cancer type separately because of the sample size. To adjust the effect of cancer types on prognosis, 398 
we conducted multivariate analysis. Although the results of PhA as a continuous variable showed 399 
that low PhA was a poor prognostic risk factor, the reference values we used may be applicable to 400 
the Asian population but not to individuals in other countries because PhA values differ according 401 
to the population. 402 
In conclusion, our analysis suggests that PhA is short- and long-term prognosis marker for 403 
patients with gastrointestinal and HBP cancers. Further studies are required to elucidate whether 404 
nutritional interventions can improve PhA and, consequently, the prognoses in these patients. 405 
 406 
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